Date: 2014-03-13
Type of information: Clinical research agreement
Compound:
Company: Teva Pharmaceutical (Israel) National Health Service National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI) (UK)
Therapeutic area: Mental diseases - CNS diseases
Type agreement: collaboration
R&D
development
clinical research
Action mechanism:
Disease: dementia
Details: * On March 13, 2014, Teva Pharmaceutical Industries has announced a collaboration with the United Kingdom ( UK ) Government\'s National Health Service National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI). NOCRI has created a novel model that streamlines the approach to undertaking clinical development in the UK . The new model provides a single point of entry into the UK healthcare system that cuts out the inherent complexities and inefficiencies of dealing with many and varied stakeholders within the combined medical and academic network on an individual and centre by centre basis.
Teva has an extensive clinical stage pipeline that is being developed globally and as part of this collaboration plans to spend approximately $20 million on conducting trials in the UK . This agreement enables Teva to benefit from the NIHR\'s new translational research infrastructure, their ability to set-up and deliver studies, and access to well characterized cohorts of patients from within the National Health Service.
Teva has also committed to a three-year dementia research program, providing funding of up to $1 million for early stage work in UK academic and medical centres. This work will be focused on understanding targets, mechanisms and new approaches to treatment of different causes and types of dementia. As part of the agreement, NOCRI will facilitate Teva\'s access to the NIHR Biomedical Research Centres and Units in Dementia and Translational Research Partnership in Dementia. Teva will maintain the right to negotiate licenses to these targets.
Financial terms:
Latest news:
